
Shares of vaccine maker Dynavax Technologies DVAX.O rise 1.8% to $14.26
DVAX announces refinancing plan that extends the maturity of most of existing debt by four years
Will issue $225 million of new convertible notes due in 2030
New notes to replace about $185 million of existing convertible notes due in 2026, and an additional $40 million of new money will be raised
New debt has a lower interest rate of 2% and a conversion price of $18.21/share; 30% premium to the stock's last close
Co is buying back $8 mln of its own stock to keep the number of shares outstanding neutral
DVAX to get $46.5 million from unwinding derivatives to partially offset the premium paid for the existing notes
Co has 124.10 mln shares outstanding with a market cap of $1.7 bln - LSEG data
DVAX fell 11.2% in 2024